C-FLIP is involved in tumor progression of Peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Zheng, Zhong ^a   Cheng, Shu ^a   Wu, Wen ^a   Wang, Li ^a,b   Zhao, Yan ^a   Shen, Yang ^a   Janin, Anne ^b,c   Zhao, Wei Li ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Laboratory of Molecular Pathology   (China)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Apoptosis; C FLIP; Histone deacetylase inhibitor; Nf b; Peripheral T cell lymphoma

Indexed keywords

FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; PROTEIN P50; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR;

ADULT; APOPTOSIS; ARTICLE; BLOOD EXAMINATION; CANCER PATIENT; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; GENE SILENCING; GENE TARGETING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; T-CELL LYMPHOMA CELL LINE; TUMOR CELL; TUMOR GROWTH; BIOSYNTHESIS; DISEASE COURSE; DRUG EFFECTS; HEK293 CELL LINE; JURKAT CELL LINE; LYMPHOMA, T-CELL, PERIPHERAL; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DISEASE PROGRESSION; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; JURKAT CELLS; LYMPHOMA, T-CELL, PERIPHERAL; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84924104310     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0088-y     Document Type: Article

References (32)

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117:5019-5032.
2. Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
3. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
4. Reed JC, Pellecchia M: Apoptosis-based therapies for hematologic malignancies. Blood 2005, 106:408-418.
5. Shaffer AL, Rosenwald A, Staudt LM: Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002, 2:920-932.
6. Fulda S: Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. Expert Opin Ther Targets 2013, 17:195-201.
7. Valente G, Manfroi F, Peracchio C, Nicotra G, Castino R, Nicosia G, Kerim S, Isidoro C: cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br J Haematol 2006, 132:560-570.
8. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
9. Reimer P, Chawla S: Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol 2013, 6:69.
10. Al-Yacoub N, Fecker LF, Mobs M, Plotz M, Braun FK, Sterry W, Eberle J: Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J Investig Dermatol 2012, 132:2263-2274.
11. Odqvist L, Sanchez-Beato M, Montes-Moreno S, Martin-Sanchez E, Pajares R, Sanchez-Verde L, Ortiz-Romero PL, Rodriguez J, Rodriguez-Pinilla SM, Iniesta-Martinez F, Solera-Arroyo JC, Ramos-Asensio R, Flores T, Palanca JM, Bragado FG, Franjo PD, Piris MA: NIK controls classical and alternative NF-kappaB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res 2013, 19:2319-2330.
12. Pileri SA, Piccaluga PP: New molecular insights into peripheral T cell lymphomas. J Clin Investig 2012, 122:3448-3455.
13. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009, 23:1507-1514.
14. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
15. McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, Johnston PG, Mills KI, McMullin MF, Longley DB, Gilkes A: Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol 2013, 160:188-198.
16. Paz-Priel I, Houng S, Dooher J, Friedman AD: C/EBPalpha and C/EBPalpha oncoproteins regulate nfkb1 and displace histone deacetylases from NF-kappaB p50 homodimers to induce NF-kappaB target genes. Blood 2011, 117:4085-4094.
17. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Zhang N, Hopkins K, He YW: c-FLIP protects mature T lymphocytes from TCR-mediated killing. J Immunol 2008, 181:5368-5373.
19. Martin-Perez R, Niwa M, Lopez-Rivas A: ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis 2012, 17:349-363.
20. Dolcet X, Llobet D, Pallares J, Matias-Guiu X: NF-κB in development and progression of human cancer. Virchows Arch 2005, 446:475-482.
21. Furumai R, Ito A, Ogawa K, Maeda S, Saito A, Nishino N, Horinouchi S, Yoshida M: Histone deacetylase inhibitors block nuclear factor-kappaBdependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci 2011, 102:1081-1087.
22. Zhong HM, Ding QH, Chen WP, Luo RB: Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-kappaB nuclear translocation. Int Immunopharmacol 2013, 17:329-335.
23. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS: Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012, 48:3223-3231.
24. Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC, Chen S: Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat 2013, 137:93-107.
25. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Muller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W: High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9:395.
26. Marquard L, Poulsen CB, Gjerdrum LM, de Nully BP, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E: Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54:688-698.
27. Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: what are the cancer relevant targets? Cancer Lett 2009, 277:8-21.
28. Marks PA, Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107:600-608.
29. Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Hacker S, Vellanki SH, Lausen J, Debatin KM, Fulda S: Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-mycmediated downregulation of cFLIP. Oncogene 2012, 31:4677-4688.
30. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 2014, 7:11.
31. Jain S, Zain J, O'Connor O: Novel therapeutic agents for cutaneous T-cell lymphoma. J Hematol Oncol 2012, 5:24.
32. Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009, 523-531.